Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6108764 | 0.76 | KDM4C (0.45) | SMN1; SMN2LMNATP53HTTMEN1 | |
| SCHEMBL6944134 | 0.74 | ALDH1A1 (0.62) | SMN1; SMN2ALDH1A1LMNATSHRTP53 | |
| SCHEMBL20665112 | 0.71 | LMNA (0.61) | SMN1; SMN2ALDH1A1LMNATSHRTP53 | |
| SCHEMBL29832042 | 0.70 | TGFBR1 (0.56) | SMN1; SMN2ALDH1A1LMNATSHRHTT | |
| SCHEMBL18834589 | 0.70 | SLC9A1 (0.48) | ALDH1A1LMNATSHRMEN1KMT2A | |
| SCHEMBL13316560 | 0.70 | MEN1 (0.45) | MEN1KMT2AKDM4C | |
| SCHEMBL5858037 | 0.70 | MEN1 (0.45) | MEN1KMT2AKDM4C | |
| SCHEMBL7242139 | 0.69 | CCR3 (0.50) | SMN1; SMN2ALDH1A1LMNATSHRTP53 | |
| SCHEMBL13085873 | 0.69 | DRD2 (0.58) | — | |
| SCHEMBL8197550 | 0.69 | SIGMAR1 (0.49) | ALDH1A1TSHRTP53HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030195352-A1 | Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2003-10-16 | — | — | US | disclosed |
| EP-1244450-A4 | 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20030018038-A1 | 1,4 substituted piperidinyl NMDA/NR2B antagonists | MERCK & CO., INC. | 2003-01-23 | — | — | US | disclosed |
| US-6476041-B1 | 1,4 substituted piperidinyl NMDA/NR2B antagonists | MERCK & CO., INC. | 2002-11-05 | — | — | US | disclosed |
| EP-1244450-A1 | 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| US-6432976-B1 | ANALGESICS; SIDE EFFECT REDUCTION | MERCK & CO., INC. | 2002-08-13 | — | — | US | disclosed |
| WO-2001032179-A1 | 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018038-A1 | 1,4 substituted piperidinyl NMDA/NR2B antagonists | GRIN1, GRIN2A, GRIN2B | SMN1; SMN2 761/4885ALDH1A1 2346/4885LMNA 4661/4885 |
| US-20030195352-A1 | Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists | ADRB3, ADRB1, ADRB2 | SMN1; SMN2 1597/4885ALDH1A1 106/4885LMNA 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.